Science Explorer Interactive view Map
Company · Tokyo · Japan

Daiichi-Sankyo (Japan)

In research, Daiichi-Sankyo (Japan) stands highest in Medicine (#5,328 of 10,443 worldwide), Health Sciences (#6,964 of 11,982 worldwide) and Life Sciences (#4,749 of 7,800 worldwide), 2022–2025. Relative to its size it is most specialised in Molecular Biology — Molecular Biology is 6.4× its share of world research.

daiichisankyo.comROR OpenAlex
World rank, 2022–2025
#10,426
of 28,054 · #6,804 all time
Rank in Japan
#257
of 1,070
Research works
2.3k
▼ 4% vs 2013–17
Citations
57k
24.8 per fractional work
Top-10% rate
15.8%
record average 16.5%
Open access
31%
world 28%

What is Daiichi-Sankyo (Japan) known for in research?

The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorksAll time
MedicineField #5,328 of 10,443 18.4%82 #3931
Health SciencesDomain #6,964 of 11,982 18.9%84 #5371
Life SciencesDomain #4,749 of 7,800 15.1%67 #3380

Each strip is that field’s whole ranked pool, with the notch where Daiichi-Sankyo (Japan) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).

Which of those standings moved

The same fields on both windows: where it stood over the whole record, and where it stands in 2022–2025. The distance is the story, and it is the one thing the two rank columns above cannot show.

  1. Medicine#3,931 #5,328
  2. Health Sciences#5,371 #6,964
  3. Life Sciences#3,380 #4,749
all time2022–2025, better2022–2025, worse

A dot further right is a better standing. Fields it was not ranked in over the whole record are left out.

What does Daiichi-Sankyo (Japan) specialise in?

Where its research is concentrated relative to its size: Molecular Biology takes 6.4× the share of its output that it takes of world research.

  1. Molecular BiologySubfield · 33.8 works6.4×
← less than its size predicts1×more →

Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.17× its world share, 1 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 4.91× its world share, 46 worksBiochemistry, Geneti…Immunology and Microbiology: 5.16× its world share, 9 worksImmunology and Micro…Neuroscience: 1.74× its world share, 5 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 9.39× its world share, 6 worksPharmacology, Toxico…Chemical Engineering: 0.54× its world share, 0 worksChemical EngineeringChemistry: 2.20× its world share, 6 worksChemistryComputer Science: 0.29× its world share, 4 worksComputer ScienceEarth and Planetary Sciences: 0.02× its world share, 0 worksEarth and Planetary …Engineering: 0.23× its world share, 6 worksEngineeringEnvironmental Science: 0.02× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.38× its world share, 2 worksMaterials ScienceMathematics: 0.20× its world share, 0 worksMathematicsPhysics and Astronomy: 0.05× its world share, 0 worksPhysics and AstronomyDentistry: 0.41× its world share, 0 worksDentistryHealth Professions: 0.08× its world share, 0 worksHealth ProfessionsMedicine: 2.44× its world share, 82 worksMedicineNursing: 1.68× its world share, 1 worksNursingVeterinary: 0.30× its world share, 0 worksVeterinaryBusiness, Management and Accounting: 0.01× its world share, 0 worksBusiness, Management…Decision Sciences: 0.83× its world share, 1 worksDecision SciencesEconomics, Econometrics and Finance: 0.54× its world share, 2 worksEconomics, Econometr…Psychology: 0.04× its world share, 0 worksPsychologySocial Sciences: 0.03× its world share, 1 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 9.4×. Every wedge is a field page.

Who are the top researchers at Daiichi-Sankyo (Japan)?

Ranked on the composite score, I Hayakawa, Atsushi Kurihara and Akira Ito lead among researchers whose main affiliation is Daiichi-Sankyo (Japan).

  1. 1 I Hayakawa Japan · #182,595 worldwide 63 citations · 28 works
  2. 2 Atsushi Kurihara Japan · #294,882 worldwide 72 citations · 20 works
  3. 3 Akira Ito Japan · #466,668 worldwide 56 citations · 19 works
  4. 4 Yasuyuki Abe Japan · #526,861 worldwide 26 citations · 26 works
  5. 5 Hideki Kobayashi Japan · #684,063 worldwide 34 citations · 23 works
  6. 6 Yasuteru Iijima Japan · #862,789 worldwide 64 citations · 15 works
  7. 7 Eiichi Nakajima Japan · #885,255 worldwide 34 citations · 18 works
  8. 8 Atsushi Sanbuissho Japan · #944,651 worldwide 44 citations · 15 works
  9. 9 Shuichi Tanabe Japan · #985,372 worldwide 33 citations · 15 works
  10. 10 Kenichi Sato Japan · #1,030,332 worldwide 65 citations · 138 works
All ranked researchers at Daiichi-Sankyo (Japan)

Which keywords describe research at Daiichi-Sankyo (Japan)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Breast Cancer, Monoclonal Antibody, Trastuzumab, Monoclonal Antibodies, Glycosylation, Receptor tyrosine kinases and Metastatic.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Chemotherapy16▲ 13×18 topics
  2. Inflammation10▲ 2.8×41 topics
  3. Breast Cancer10▲ 23×6 topics
  4. Monoclonal Antibody9▲ 103×2 topics
  5. Cancer9▲ 3.7×27 topics
  6. Trastuzumab8▲ 101×2 topics
  7. Monoclonal Antibodies8▲ 51×3 topics
  8. Glycosylation8▲ 40×3 topics
  9. Receptor tyrosine kinases8▲ 126×2 topics
  10. EGFR8▲ 154×1 topic
  11. HER28▲ 154×1 topic
  12. Metastatic8▲ 71×2 topics
  13. Therapeutic Antibodies8▲ 62×2 topics
  14. Hypertension6▲ 12×9 topics
  15. Clinical Trials6▲ 5.1×10 topics
  16. Biomarkers5▲ 4.5×13 topics
  17. Cancer Therapy5▲ 5.4×11 topics
  18. Cardiovascular Events5▲ 25×3 topics
  19. Antibody Engineering5▲ 53×1 topic
  20. Cardiovascular Disease5▲ 2.6×17 topics
  21. Fc Receptors5▲ 53×1 topic
  22. Immunotherapy5▲ 4.1×13 topics
  23. Targeted Therapy5▲ 12×4 topics
  24. Metastasis4▲ 7.2×7 topics
  25. Clinical Practice Guidelines4▲ 4.4×10 topics
  26. Prognostic Factors4▲ 5.5×10 topics
  27. Tumor Microenvironment4▲ 5.2×7 topics
  28. Drug Discovery4▲ 9.6×5 topics
  29. Lymphoma4▲ 13×4 topics
  30. Biopharmaceuticals4▲ 39×3 topics
  31. Cell Signaling4▲ 13×8 topics
  32. Pharmacokinetics3▲ 7.5×4 topics
  33. Transcriptional Regulation3▲ 12×7 topics
  34. Metastatic Breast Cancer3▲ 32×2 topics
  35. Gene Therapy3▲ 9.2×4 topics
  36. PET Imaging3▲ 10×4 topics
  37. Recombinant Proteins3▲ 56×2 topics
  38. Cancer Immunotherapy3▲ 11×3 topics
  39. Diabetes Mellitus3▲ 8.6×5 topics
  40. Neurotoxicity3▲ 14×4 topics

Which research topics does Daiichi-Sankyo (Japan) publish most on?

By volume in 2022–2025: HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Hormonal Regulation and Hypertension and Protein purification and stability.

HER2/EGFR in Cancer Rese…8HER2/EGFR in Cancer Research: 8 fractional worksMonoclonal and Polyclonal Antibodies Research: 5 fractional worksHormonal Regulation and Hypertension: 3 fractional worksProtein purification and stability: 2 fractional worksLung Cancer Treatments and Mutations: 2 fractional worksCancer Treatment and Pha…2Cancer Treatment and Pharmacology: 2 fractional worksAtrial Fibrillation Management and Outcomes: 2 fractional worksViral Infectious Diseases and Gene Expression in Insects: 2 fractional worksPharmacogenetics and Drug Metabolism: 2 fractional worksReceptor Mechanisms and Signaling: 2 fractional works
OncologyRadiology, Nuclear Medicine and ImagingEndocrinology, Diabetes and MetabolismMolecular Biology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 HER2/EGFR in Cancer Research Oncology 8 works
  2. 2 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 5 works
  3. 3 Hormonal Regulation and Hypertension Endocrinology, Diabetes and Metabolism 3 works
  4. 4 Protein purification and stability Molecular Biology 2 works
  5. 5 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
  6. 6 Cancer Treatment and Pharmacology Oncology 2 works
  7. 7 Atrial Fibrillation Management and Outcomes Cardiology and Cardiovascular Medicine 2 works
  8. 8 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 2 works
  9. 9 Pharmacogenetics and Drug Metabolism Pharmacology 2 works
  10. 10 Receptor Mechanisms and Signaling Molecular Biology 2 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available31.3%not open68.7%

World: 28% of research is openly available.

with international co-authors24.2%domestic only75.8%

World: 19% is written across borders.

How has Daiichi-Sankyo (Japan)'s research output changed?

Output in 2018–2022 was 4% lower than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Tokyo

All research institutions in Tokyo

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.